Delayed High-Dose Intravesical Epirubicin Therapy of Superficial Bladder Cancer

Publisher： Karger

E-ISSN： 1423-0399|68|4|216-219

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.68, Iss.4, 2002-05, pp. : 216-219

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bacillus Calmette-Guérin versus Gemcitabine for Intravesical Therapy in High-Risk Superficial Bladder Cancer: A Randomised Prospective Study

By  

Urologia Internationalis, Vol. 84, Iss. 1, 2010-02 ,pp. : 23-27

Karger

Access to resources Recommend Favorite

Intravesical Therapy for Superficial Bladder Carcinoma

By  

Oncology Research and Treatment, Vol. 22, Iss. 6, 2000-01 ,pp. : 462-462

Karger

Access to resources Recommend Favorite

Intravesical Bacillus Calmette-Guérin Therapy for T1 Superficial Bladder Cancer

By  

Urologia Internationalis, Vol. 80, Iss. 1, 2008-01 ,pp. : 74-79

Karger

Access to resources Recommend Favorite

Intravesical Combined Chemoimmunotherapy with Epirubicin and Bacillus Calmette-Guérin Is Not Indicated for Superficial Bladder Cancer

By  

Urologia Internationalis, Vol. 67, Iss. 4, 2001-12 ,pp. : 289-292

Karger

Access to resources Recommend Favorite

Cytological Changes Induced by Intravesical Bacillus Calmette-Guérin Therapy for Superficial Bladder Cancer

By  

Urologia Internationalis, Vol. 64, Iss. 2, 2000-05 ,pp. : 74-81

Karger

Access to resources Recommend Favorite